QIAGEN to Showcase New Sample to Insight Solutions for Oncology Research at AACR 2026

Highlights solutions addressing key oncology research needs across automated sample preparation, single-cell analysis, genomic profiling and data analysis

Apr. 16, 2026 at 8:07pm

Got story updates? Submit your updates here. ›

A bold, abstract painting in soft blues, greens, and oranges featuring sweeping geometric shapes, concentric circles, and precise organic spirals, conceptually representing the complexity and structure of multi-omics data analysis for oncology research.QIAGEN's integrated oncology workflow solutions aim to standardize critical steps from sample preparation to data interpretation, enabling more consistent, reproducible, and insightful cancer research.San Diego Today

QIAGEN N.V. announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrating how its portfolio connects sample preparation with multi-omics profiling and genomic data interpretation to support cancer research and molecular diagnostics.

Why it matters

Cancer research and molecular diagnostics are increasingly constrained by fragmented workflows, variability in sample processing and the growing complexity of multi-omics data. QIAGEN aims to help standardize critical steps from sample preparation through data interpretation, enabling more consistent results, improved reproducibility and more confident insights from complex biological data.

The details

At the AACR Annual Meeting 2026, QIAGEN will showcase applications across key stages of the oncology workflow, from sample preparation to genomic profiling and data interpretation. This includes new instruments and kits for single-cell analysis, the upcoming IVD QIAsymphony Connect automation platform, new QIAseq research panels for next-generation sequencing, and the new QIAGEN Discovery Platform for AI-powered drug discovery support.

  • The AACR Annual Meeting 2026 will take place from April 17–22 in San Diego.
  • QIAsymphony Connect is an upcoming IVD system that builds on over 3,300 placements of the established QIAsymphony platform.
  • QIAsprint Connect for research use only was launched at the SLAS 2026 meeting in February and is now progressing through commercialization.
  • The Evercode Whole Transcriptome v4 kit and the Evercode Whole Transcriptome FFPE kit from Parse Biosciences are now shipping.

The players

QIAGEN N.V.

A global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples.

Nitin Sood

Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN.

Parse Biosciences

A QIAGEN company that will highlight its Evercode single-cell analysis portfolio at AACR.

Myriad Genetics

QIAGEN developed the QIAseq xHYB HRD Panel in collaboration with Myriad Genetics to support research into homologous recombination deficiency.

Element Biosciences

The new QIAseq xHYB Trinity DNA/RNA Kit is designed for use with Element's Trinity sequencing workflow.

Got photos? Submit your photos here. ›

What they’re saying

“Cancer research and molecular diagnostics are increasingly constrained by fragmented workflows, variability in sample processing and the growing complexity of multi-omics data.”

— Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN

What’s next

QIAGEN will showcase its oncology workflow solutions at the AACR Annual Meeting 2026 in San Diego from April 17-22.

The takeaway

QIAGEN is addressing key pain points in cancer research and molecular diagnostics by integrating sample preparation, multi-omics profiling, and data analysis into more standardized and automated workflows. This aims to improve reproducibility, efficiency and confidence in insights derived from complex biological data.